The reversibility of this weight loss without apparent decreases of mouse viability suggests the potential value of liver GCN1 as a drug target for obesity or non-alcoholic fatty liver disease leading to insulin resistance, the most prevalent non-communicable disease in the world. Here, GCN1 is linked to obesity disorder.